Literature DB >> 6524907

Ciprofloxacin penetration into extravascular spaces in a rabbit model.

K L Nichol, L R Peterson, C E Fasching, D N Gerding.   

Abstract

Ciprofloxacin penetration into extravascular spaces was studied in a rabbit Visking chamber model. The drug was administered (7 mg/kg) intramuscularly every 4 h for eight doses. Peak and trough drug levels by dose 8 were 1.3 and 0.35 micrograms/ml in serum and 0.61 and 0.50 micrograms/ml in extravascular sites. The ratio of extravascular site to serum free drug area under the drug curve by dose 8 was 91.1%. This potent, new antimicrobial agent appears to distribute freely to extravascular spaces in this animal model.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6524907      PMCID: PMC180055          DOI: 10.1128/AAC.26.6.935

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Standardization of a preparative ultracentrifuge method for quantitative determination or protein binding of seven antibiotics.

Authors:  L R Peterson; W H Hall; H H Zinneman; D N Gerding
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

2.  Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.

Authors:  C Roy; A Foz; C Segura; M Tirado; M Teixell; D Teruel
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

3.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

7.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Prediction of cefazolin penetration in high- and low-protein-containing extravascular fluid: new method for performing simultaneous studies.

Authors:  L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

View more
  4 in total

1.  Efficacy of ciprofloxacin in an experimental model of Escherichia coli chorioamnionitis in rabbits.

Authors:  Elise Launay; Nicolas Joram; Cédric Jacqueline; Anne Francoise Miegeville; Jocelyne Caillon; Gilles Potel; Jean Christophe Roze; Christèle Gras-Le Guen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

2.  Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; M F Michel
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

3.  Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding.

Authors:  G Potel; N P Chau; B Pangon; B Fantin; J M Vallois; F Faurisson; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  Ciprofloxacin in the treatment of pneumonia.

Authors:  J A Ernst; E R Sy; H Colon-Lucca; N Sandhu; T Rallos; V Lorian
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.